Miranda Reed, DO
Interventional Pain Medicine · Cumming, GANPI 1659684231
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,691 of the $9,329 with a category attached, or 61.0%. Boston Scientific accounts for 69.2% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $2,666 and has fallen 65.8% since, to $911 in 2025.
Across 166 payments — averaging $56.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$6K
- Nevro Corp.$885
- SPR Therapeutics, Inc$660
- LEO Pharma Inc.$349
- Sun Pharmaceutical Industries Inc.$171
- Galderma Laboratories, L.p.$134
- plus $677 from 18 others
What the payments were for
- Travel & lodging$3,63939%
- Food & beverage$5,69161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 101 | $6,453 |
| Nevro Corp. | 6 | $885 |
| SPR Therapeutics, Inc | 5 | $660 |
| LEO Pharma Inc. | 13 | $349 |
| Sun Pharmaceutical Industries Inc. | 9 | $171 |
| Galderma Laboratories, L.p. | 1 | $134 |
| Mayne Pharma Commercial LLC | 3 | $72 |
| AbbVie(2 entities) | 4 | $71 |
| Abbott | 3 | $65 |
| Pacira Therapeutics, Inc. | 3 | $52 |
| Avanos Medical | 1 | $50 |
| Medtronic | 2 | $40 |
| Journey Medical Corporation | 1 | $40 |
| Biotronik NRO, Inc. | 1 | $39 |
| Lilly USA, LLC | 2 | $38 |
| Johnson & Johnson | 2 | $37 |
| Amgen(2 entities) | 2 | $30 |
| VYNE Pharmaceuticals Inc. | 1 | $30 |
| Novartis | 1 | $22 |
| MML US, Inc. | 1 | $20 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $20 |
| Merz North America, Inc. | 1 | $19 |
| Pfizer | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPECTRA WAVEWRITER$1,456
- WAVEWRITER ALPHA$1,093
- Senza Spinal Cord Stimulation System$710
- GENERAL PAIN MANAGEMENT$697
- SPRINT PNS System$582
- WaveWriter Alpha Prime 16$279
- EPIDUO FORTE$134
- SOOLANTRA$134
- ORACEA$134
- Omnia$123
How this compares
$9,329 in reported general payments places this provider in the 70th percentile of 129 interventional pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 65 | $39,397 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 894 | $29,736 |
| Buprenorphine | 109 | $29,104 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,205 | $26,953 |
| Fentanyl | 71 | $8,271 |
| Naloxone Hcl | 80 | $5,615 |
| Oxycodone Hcl | 243 | $5,029 |
| Pregabalin | 186 | $4,880 |
| Morphine Sulfate ErMorphine Sulfate | 220 | $4,469 |
| Gabapentin | 190 | $2,677 |
| Celecoxib | 93 | $1,587 |
| Tizanidine Hcl | 60 | $1,315 |
| Morphine Sulfate | 42 | $1,297 |
| Lidocaine | 13 | $1,289 |
| Tramadol Hcl | 156 | $1,193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $14 | $30,401151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 129 interventional pain medicine providers in Georgia.
Other interventional pain medicine in Cumming
- Ezra RiberCumming$5K
- Emmanuel GageBrunswick$602K
- Jordan TateJasper$540K
- Christopher BovinetBrunswick$338K
- David RosenfeldCovington$249K
- Nathan NeufeldNewnan$171K
- Ryan BudwanyLawrenceville$123K
- Alexandra MoreiraAtlanta$79K
- Sushanth BodaNewnan$55K
- Christopher AndrianoStockbridge$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.